On March 17, 2026 Revolution Medicines, Inc. (Nasdaq:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, reported that nine oral and poster presentations highlighting advances across its RAS(ON) inhibitor pipeline will be featured at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, taking place April 17–22, 2026 in San Diego.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentations will include new Phase 1 data for zoldonrasib, a RAS(ON) G12D-selective inhibitor, in patients with previously treated KRAS G12D mutant non-small cell lung cancer, which will be featured in a plenary session.

The company will also present two Phase 1/2 datasets evaluating daraxonrasib, a RAS(ON) multi-selective inhibitor, in patients with first line metastatic pancreatic ductal adenocarcinoma (PDAC), including monotherapy data and daraxonrasib plus chemotherapy combination data, the latter of which will be featured in a mini-symposium session.

Additional presentations will highlight preclinical research supporting a new class of mutant-targeted catalytic RAS(ON) inhibitors, designed to maintain antitumor activity in the setting of emergent resistance.

Together, these presentations reflect the breadth of Revolution Medicines’ RAS(ON)-focused development strategy, spanning clinical studies across multiple tumor types and ongoing discovery efforts to address resistance and expand therapeutic opportunities for patients with RAS-driven cancers.

Details of the presentations are listed below.

Revolution Medicines Invited Presentation:

Title: Targeting the Oncogenic State of RAS: Lessons from Tri-Complex Inhibitors
Presenter: Mallika Singh, Ph.D., Revolution Medicines
Session: How KRAS Inhibitors Got to the Clinic: From Discovery to Patient Benefit
Date/Time: April 18; 3:00 p.m. – 3:20 p.m. PST

Revolution Medicines Oral Presentation:

Title: Preliminary Safety and Clinical Activity of Zoldonrasib (RMC-9805), an Oral, RAS(ON) G12D-Selective, Tri-Complex Inhibitor in Patients with Previously Treated KRAS G12D Non-Small Cell Lung Cancer (NSCLC)
Presenter: Jonathan Reiss, M.D., UC Davis Comprehensive Cancer Center
Abstract
Number: CT021
Session: New Frontiers in Precision Oncology
Date/Time: April 19; 1:30 p.m. – 1:45 p.m. PST

Revolution Medicines Mini Symposiums:

Title: Daraxonrasib plus Chemotherapy as First Line Treatment for Patients with Metastatic Pancreatic Adenocarcinoma (mPDAC)
Presenter: Brian Wolpin, M.D., Dana-Farber Cancer Institute
Abstract
Number: LB407
Session: Late-Breaking Research
Date/Time: April 21; 4:05 p.m. – 4:20 p.m. PST

Title: Discovery of a New Class of Mutant-Targeted Catalytic RAS(ON) Inhibitors with Retained Antitumor Activity in Setting of Emergent Resistance Due to Elevated RAS Flux
Presenter: Jacqueline (Jan) Smith, Ph.D., Revolution Medicines
Abstract
Number: 6782
Session: Targeted Protein Degradation and Non-canonical Oncogenic Signaling
Date/Time: April 21; 4:05 p.m. – 4:20 p.m. PST

Revolution Medicines Posters:

Title: RAS(ON) Inhibition in both Cancer and Immune Cells by Daraxonrasib Drives Antitumor Immunity
Presenter: Nataliya Shifrin, Ph.D., Revolution Medicines
Abstract
Number: 2831
Session: Immune Mechanisms Invoked by Other Therapies and Exposures
Date/Time: April 20; 2:00 p.m. – 5:00 p.m. PST

Title: RASolve 301: A Phase 3 Study of Daraxonrasib (RMC-6236) vs. Docetaxel in Patients with Previously Treated RAS-mutant NSCLC
Presenter: Ferdinandos Skoulidis, M.D., Ph.D., MRCP, MD Anderson Cancer Center
Abstract
Number: CT215
Session: Late-Breaking Research
Date/Time: April 21; 9:00 a.m. – 12:00 p.m. PST

Title: Daraxonrasib Monotherapy as First Line Treatment for Patients with Metastatic Pancreatic Adenocarcinoma
Presenter: Eileen O’Reilly, M.D., Memorial Sloan Kettering Cancer Center
Abstract
Number: LB337
Session: Late-Breaking Research: Clinical Research 3
Date/Time: April 21; 2:00 p.m. – 5:00 p.m. PST

Title: RAS(ON) Multi-Selective Inhibitors Stimulate the Hydrolysis of RAS-GTP to RAS-GDP and Drive Synergistic Combination Benefit with KRAS(OFF) Inhibitors in G12 Mutant Tumors
Presenter: Kyle Seamon, Ph.D., Revolution Medicines
Abstract
Number: 5696
Session: Mechanisms of Anticancer Drug Action
Date/Time: April 21; 2:00 p.m. – 5:00 p.m. PST

Collaborator Mini Symposium:

Title: Active RAS Inhibition Intercepts Pancreas Cancer in Mice
Presenter: Ben Stanger, M.D., Ph.D., Penn Pancreatic Cancer Research Center
Abstract
Number: LB406
Session: Late-Breaking Research
Date/Time: April 21; 3:50 p.m. – 4:05 p.m. PST

(Press release, Revolution Medicines, MAR 17, 2026, View Source [SID1234663624])

On March 17, 2026 Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), reported a strategic collaboration with BobcatBio, a clinical-stage biotechnology company that is pioneering the development of RB-1355, a first of its kind cellular therapy that leverages the versatility and power of a patient’s macrophages to elicit a robust, targeted tumoricidal immune response while substantially reducing or eliminating the reliance on traditional cancer treatments such as chemotherapy, high-dose radiation and surgery, thereby improving patient outcomes and quality of life. This breakthrough approach holds transformative potential to redefine cancer treatment, offering the prospect of becoming a preferred therapy across a wide spectrum of solid tumors and lymphomas. Early clinical findings in relapsed or refractory non-Hodgkin lymphoma indicate that RB-1355 is well tolerated with encouraging early signs of activity. Recent clinical data also demonstrated that the therapy can be effectively administered without lymphodepleting chemotherapy and in multiple doses from a single apheresis through cryopreservation.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the agreement, Cellipont Bioservices will perform Phase I cell product manufacturing of RB-1355 in support of BobcatBio’s ongoing solid tumor and lymphoma clinical trials.

"At Cellipont, we are committed to supporting innovators who are pushing the boundaries of what cell therapy can do for patients," said Darren Head, CEO, Cellipont Bioservices. "BobcatBio’s work reflects the kind of bold science this field needs, and we are proud to support the advancement of a program with the potential to open new possibilities in solid tumors. Collaborations like this are about more than manufacturing. They are about helping bring promising therapies closer to patients and families who are waiting for better options."

"BobcatBio is advancing a highly differentiated approach to cell therapy, and we are pleased to partner with Cellipont as we continue to move this program forward," said Stephen Rocamboli, CEO, BobcatBio "As we work to bring our macrophage-based therapy closer to patients, it is critical to have a manufacturing partner that understands both the complexity of cell therapy development and the urgency of delivering new treatment options. Cellipont brings the technical expertise, quality focus, operational rigor, and scalable infrastructure needed to advance BobcatBio’s innovative cellular therapy."

(Press release, BobcatBio, MAR 17, 2026, View Source [SID1234663641])

On March 17, 2026 Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, reported that four abstracts highlighting the latest preclinical results from its pipeline programs have been selected for poster presentations at the American Association of Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026, taking place April 17-22, 2026, in San Diego, CA, USA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The data to be presented encompasses three of the Company’s novel drug candidates: BCR-ABL tyrosine kinase inhibitor Olverembatinib (HQP1351), FAK/ALK/ROS1 tyrosine kinase inhibitor APG-2449, and PRC2/EED inhibitor APG-5918.

The AACR (Free AACR Whitepaper) Annual Meeting 2026 is the critical driver of progress against cancer, the place where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share and discuss the latest breakthroughs. From population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy; the AACR (Free AACR Whitepaper) Annual Meeting showcases cutting-edge cancer science and medicine.

The four preclinical abstracts from Ascentage Pharma include:

Multitarget kinase inhibitor olverembatinib (HQP1351) is efficacious and synergizes with chemotherapy in preclinical models of endometrial carcinoma (EC)

Abstract#: 4583
Poster Session Category: Experimental and Molecular Therapeutics
Session Title: Novel Antitumor Agents 2
Time: Tuesday, April 21, 2026, 9:00 AM – 12:00 PM PDT

Multikinase inhibitor olverembatinib (HQP1351) is efficacious and synergizes with BTK inhibitor acalabrutinib in mantle cell lymphoma (MCL) preclinical models

Abstract#: 5875
Poster Session Category: Experimental and Molecular Therapeutics
Session Title: Tyrosine Kinase, Phosphatase, and Other Inhibitors
Time: Tuesday, April 21, 2026, 2:00 PM – 5:00 PM PDT

FAK inhibition by APG-2449 enhances the antitumor activity of MAPK pathway blockade in BRAF V600E-mutant tumor models

Abstract#: 1858
Poster Session Category: Experimental and Molecular Therapeutics
Session Title: Targeting Drug Resistance 1: Apoptosis and Autophagy
Time: Monday, April 20, 2026, 9:00 AM – 12:00 PM PDT

Embryonic ectoderm development (EED) inhibitor APG-5918 synergizes with topoisomerase I inhibitors in preclinical small-cell lung cancer (SCLC) models through epigenetic priming of chemosensitivity

Abstract#: 4500
Poster Session Category: Experimental and Molecular Therapeutics
Session Title: Epigenetic Modulators 1
Time: Tuesday, April 21, 2026, 9:00 AM – 12:00 PM PDT

*Olverembatinib, APG-2449, and APG-5918 are currently under investigation and have not been approved by the U.S. FDA.

(Press release, Ascentage Pharma, MAR 17, 2026, View Source [SID1234663657])

On March 17, 2026 Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, reported two poster presentations at the 2026 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, taking place April 17-22, 2026, in San Diego, CA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are excited to highlight the potential to expand the opportunity for azenosertib as a combination therapy with cytotoxic agents, including antibody drug conjugates (ADC) and chemotherapy, for Triple-Negative Breast Cancer, a subtype of breast cancer with elevated Cyclin E1 expression. These data support clinical study of azenosertib in tumor types beyond ovarian cancer," said Julie Eastland, Chief Executive Officer. "In addition, the Cyclin E1 biomarker findings in ovarian cancer based on real world data reinforce the high unmet need for this biomarker-selected patient population with poor prognosis. Our biomarker-driven strategy for azenosertib monotherapy in Cyclin E1-positive platinum-resistant ovarian cancer has potential to address this unmet need."

AACR poster presentation details are below:

Title: "WEE1 Inhibition as a Therapeutic Strategy in Triple-Negative Breast Cancer: Evaluating Single Agent and Combination Activity of Azenosertib in Preclinical Models"
Abstract Number: 2012
Date/Time: Monday, April 20, 2026, 2:00 p.m. – 5:00 p.m. PDT
Presenting Author: Alexandra Levy, MS

Title: "Real-World Treatment Patterns and Outcomes Reveal Distinct Clinical Trajectories of Patients with Cyclin E1-Positive Ovarian Cancer"
Abstract Number: 1708
Date/Time: Sunday, April 19, 2026, 2:00 p.m. – 5:00 p.m. PDT
Presenting Author: Jinkil Jeong, PhD

The posters can be accessed on the Supporting Publications page of the Zentalis website at the time of each presentation’s session.

About Azenosertib
Azenosertib is an investigational, potentially first-in-class, selective, and orally bioavailable inhibitor of WEE1 currently being evaluated in clinical studies in ovarian cancer and additional tumor types. WEE1 acts as a master regulator of the G1-S and G2-M cell cycle checkpoints, through negative regulation of both CDK1 and CDK2, to prevent replication of cells with damaged DNA. By inhibiting WEE1, azenosertib enables cell cycle progression, despite high levels of DNA damage, thereby resulting in the accumulation of DNA damage and leading to mitotic catastrophe and cancer cell death.

Azenosertib is in late-stage development as a potential treatment for Cyclin E1-positive platinum-resistant ovarian cancer (PROC). There is currently no approved treatment option specifically for this biomarker-selected population which comprises approximately 50% of PROC patients. Cyclin E1 protein overexpression has been established as a sensitive and specific predictive biomarker for identifying patients who could potentially derive benefit from azenosertib treatment.

(Press release, Zentalis Pharmaceuticals, MAR 17, 2026, View Source [SID1234663673])

On March 17, 2026 Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, reported that the Israeli Patent Office has allowed its patent application No. 284463, titled "An A3 Adenosine Receptor Ligand for Use for Achieving a Fat Loss Effect." The allowed patent covers the use of A3 adenosine receptor (A3AR) agonists, including the Company’s lead drug candidate Namodenoson, for inducing fat loss and treating obesity and related metabolic disorders.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This allowance represents a key addition to Can-Fite’s expanding global intellectual property portfolio around Namodenoson’s anti-obesity activity and follows similar patent advancements in other major jurisdictions including the US, Canada and Australia, strengthening the Company’s worldwide protection strategy. Recently the technology granted scientific recognition upon coming up with a breakthrough publication of peer-reviewed study in the International Journal of Obesity, demonstrating the anti-obesity effect of namodenoson (View Source ).

The global obesity therapeutics market is experiencing rapid growth, driven by increasing prevalence and the success of GLP-1 receptor agonists. However, current treatments are often associated with limitations including gastrointestinal side effects and high cost. Namodenoson, a highly selective A3AR agonist, offers a differentiated mechanism of action, targeting key pathways involved in adipogenesis, inflammation, and metabolic regulation. Preclinical and clinical studies have demonstrated its potential to reduce fat accumulation and improve metabolic profiles, positioning it as a promising candidate in the expanding obesity treatment landscape.

"With the allowance of this patent in Israel, we continue to build and strengthen our intellectual property portfolio around Namodenoson’s anti-obesity activity," said Dr. Pnina Fishman, Chairperson and Chief Scientific Officer of Can-Fite. "Given the significant unmet need and rapid growth of the obesity market, we believe Namodenoson’s unique mechanism and established safety profile position it as an attractive candidate for development and potential partnering opportunities."

The global obesity treatment market is projected to reach $60.5 billion by 2030, growing at a compound annual growth rate (CAGR) of approximately 22%, driven by increasing disease prevalence and demand for safe, effective oral therapies.

About Namodenoson

Namodenoson is a small orally bioavailable drug that binds with high affinity and selectivity to the A3 adenosine receptor (A3AR). Namodenoson is currently being evaluated in a pivotal Phase III trial for advanced liver cancer, a Phase IIb trial for the treatment of Metabolic Dysfunction-associated Steatohepatitis (MASH), and in a Phase IIa study in pancreatic cancer. A3AR is highly expressed in diseased cells whereas low expression is found in normal cells. This differential expression may be one of the important factors that accounts for the excellent safety profile of the drug.

(Press release, Can-Fite BioPharma, MAR 17, 2026, View Source [SID1234663609])